market Inner Banner
  • BSE
  • NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ticker-arrow
    • ({{d.PerChg}}%)
Equity | News | Hot Pursuit
Hot Pursuit
Mylan exits Biocon with Rs 3,679 crore block deal; ICICI Prudential MF emerges largest buyer
(11:50, 15 Jul 2026)
Mylan sold around 9.19 crore shares, representing its entire 5.64% stake, at Rs 400 per share across the BSE and NSE.

The block deal witnessed strong participation from domestic and foreign institutional investors. ICICI Prudential Mutual Fund emerged as the largest buyer, acquiring 3.69 crore shares (2.26% stake). HDFC Mutual Fund and Kotak Mahindra Mutual Fund each purchased 1.16 crore shares (0.71% stake), while SBI Mutual Fund acquired 50 lakh shares (0.31% stake). ICICI Prudential Life Insurance bought 25 lakh shares (0.15% stake). Aditya Birla Sun Life Mutual Fund, Franklin Templeton Mutual Fund and Mirae Asset Mutual Fund acquired 18.75 lakh shares (0.12% stake) each, while Tata Mutual Fund purchased 6.26 lakh shares (0.04% stake).

Other investors, including Axis Mutual Fund, UTI Mutual Fund, Mahindra Mutual Fund, IDFC Mutual Fund, HDFC Life Insurance, Bajaj Life Insurance, Norges Bank, Goldman Sachs Bank Europe, Morgan Stanley Asia Singapore, Societe Generale, Vanguard Emerging Markets Shares Index Fund, WhiteOak Capital Mutual Fund, Authum Investment & Infrastructure, Abakkus Growth Fund, Canara Robeco Mutual Fund and Eastspring Investments Asian Low Volatility Equity Fund, each acquired 6.26 lakh shares (0.04% stake). Citigroup Global Markets Singapore and BNP Paribas Arbitrage purchased 7.50 lakh shares (0.05% stake) each.

Mylan's relationship with Biocon began in 2009, when the companies entered into a global collaboration to develop and commercialise biosimilars. The partnership later expanded to generic insulin analogues. Mylan became a shareholder in Biocon in January 2026 after the company issued shares as part of the acquisition of Viatris' stake in Biocon Biologics. The latest transaction marks Mylan's complete exit from Biocon.

As of 30 June 2026, Biocon's promoters held a 44.67% stake in the company, while Mylan owned 5.64%.

Biocon is a global biopharmaceutical company focused on developing affordable therapies for chronic diseases, including diabetes, cancer and autoimmune disorders.

On a consolidated basis, the company's net profit declined 63.4% YoY to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25. Revenue from operations increased 2.26% YoY to Rs 4,517 crore during the quarter.

Shares of Biocon were down 0.70% at Rs 434.25 on the NSE.

Powered by Capital Market - Live News

.
Stock Broker Name Registration Number Registered Address Branch Address Contact Number Email id
DB (International) Stock Brokers Limited INZ000179035 (BROKING)

IN-DP-CDSL-266-2004 (DEPOSITORY)
Unit No. 210/211/211A at 2nd floor, Dalal Street Commercial Cooperative Society Ltd, Block No.53, Zone 5, Gift City, Gandhinagar, Gujarat-382355
51, Mini Market T/F Mandir Wali Gali, Yusaf Sarai, New Delhi 110016 011-35936102 greenpark@dbonline.in
C-12, DB Plaza, RDC Raj Nagar, Ghaziabad 201002 0120-4150393 ghaziabad@dbonline.in
Plot No 4, Wasme House, Film City Sector 16A, Noida – 201301 0120-4823200 compliance@dbonline.in
Out Side Jassusar Gate, Bikaner, Rajasthan – 334001 9001643408 bikaner@dbonline.in
Office No 101, City Center, Opp. High Court, M G Road, Indore 452001 9424083019 brajeshsadani@dbonline.in
203, Marshal House 25, Strand Road, Kolkata 700001 033-40055270 b032@dbonline.in
Shop No.-7, 2nd Floor, Amar Complex, Opp. Hanumaan Mandir, The Mall, Solan- 173212 6230604596 parwanoo@dbonline.in
Daga Commodities Private Limited INZ000028833 114, New Delhi House, 27 Barakhamba Road, Delhi 110001- 0120-4823200 compliance@dbonline.in
Daga Business (International) Stock Brokers (IFSC) Private Limited INZ000202436 Unit No. 228, Signature Building, Second Floor, Block 13B, Zone-1, Gift SEZ, Gandhinagar, Gujarat 382355 - 0120-4823200 compliance@dbonline.in

Disclosure regarding proprietary trading:

As required under Circular No. SEBI/MRD/SE/Cir-42/2003 dated 19.11.2003 issued by the Securities and Exchange Board of India; We hereby disclose that in addition to client based business, We are also doing proprietary trading.

Investor Grievances Email ID: investorgrievance@dbonline.in


Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and Maintained by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)
Attention Investors ::
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries | Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. | Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month........... Issued in the interest of Investors"